The Next Emflaza: Acer Therapeutics Looks to Take a Page Out of Marathon's Book
By Zachary Brennan -
Published 18 January 2018
Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US Food and Drug Administration's (FDA) approval process before trumpeting an $89,000 annual price.
Categories: News, US, FDA, Drugs, Regulatory intelligence, Regulatory strategy
Tags: Emflaza, Marathon, Acer, Shkreli